Ipca Laboratories has been selected by The Global Fund as their Panel Supplier of anti-malarial medicines for the Global Fund Pooled Procurement Mechanism and for the Private Sector Co-Payment Mechanism for an initial period of three years.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
